美國Vaccinex www.vaccinex.com
Vaccinex, Inc. 創(chuàng)立于1997年，位于紐約州羅切斯特，是一家非公開上市的生物科技公司，致力于人類治療用單克隆抗體和疫苗的發(fā)現(xiàn)和開發(fā)，旨在治療需求得不到滿足的嚴(yán)重疾病
美國Vaccinex 
Located in Rochester, NY, Vaccinex is a privately held, clinical-stage biotechnology company engaged in the discovery and development of human therapeutic monoclonal antibodies, therapeutic vaccines and other biologic products to treat serious diseases with unmet needs, including cancer, multiple sclerosis, and other autoimmune diseases. We conduct discovery research in-house and in collaboration with world-class academic institutions and biotechnology companies, and have an experienced in-house drug development management team to advance our pre-clinical and clinical stage biopharmaceutical development programs. Our development team is led by seasoned industry veterans with both operational and executive level biopharmaceutical industry experience in therapeutic biologics research, manufacturing, quality assurance, quality control, toxicology, pharmacology, drug regulatory affairs, and clinical affairs. Since our founding in 1997, we have been funded by private equity and by several grants from NIH and NIST, including the award of two Advanced Technology Program grants of $2 million each. In November 2009, we secured additional private financing to support the advanced pre-clinical and early clinical stages of development of our three lead therapeutic antibody programs; VX15, VX5 and VX35.
We are committed to innovation in the way we approach drug discovery and development. We are committed to identifying and advancing therapeutics that work in novel ways to address unmet medical needs. We are committed to successfully meeting the challenge of treating patients with safe and effective medicines. We are committed to the patients who may use our drugs, and to our shareholders, our employees, and our community – all stakeholders in our success.